Work on safeguarding the medicine supply chain should be accompanied by ambitious actions to ensure the future of the sector, including a new deal on competitiveness, says the pharmaceutical industry.
The launch of the EU’s Critical Medicines Alliance, aimed at improving supplies of important medicines, could be the first step towards a Critical Medicines Act designed to support production of APIs and finished medicines in the EU. However, whether such an act is feasible remains uncertain.
Meanwhile, EFPIA, which represents the innovative pharmaceutical industry in Europe, has called on EU bodies to couple action on medicine...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
